Guardant Health, Inc. (GH) Income Statement Analysis

See more : I.C.C. International Public Company Limited (ICC.BK) Income Statement Analysis – Financial Results

Complete financial analysis of Guardant Health, Inc. (GH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guardant Health, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Sealand Securities Co., Ltd. (000750.SZ) Income Statement Analysis – Financial Results
The Fertilisers And Chemicals Travancore Limited (FACT.BO) Income Statement Analysis – Financial Results
CROOZ, Inc. (2138.T) Income Statement Analysis – Financial Results
Crawford & Company (CRD-A) Income Statement Analysis – Financial Results
Tingyi (Cayman Islands) Holding Corp. (910322.TW) Income Statement Analysis – Financial Results

Guardant Health, Inc. (GH)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://guardanthealth.com

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	563.95M	449.54M	373.65M	286.73M	214.38M	90.64M	49.84M	25.25M
Cost of Revenue	227.05M	156.33M	122.91M	92.54M	70.72M	43.21M	31.62M	22.12M
Gross Profit	336.90M	293.21M	250.74M	194.20M	143.66M	47.43M	18.22M	3.13M
Gross Profit Ratio	59.74%	65.23%	67.11%	67.73%	67.01%	52.33%	36.56%	12.38%
Research & Development	367.19M	373.81M	263.22M	149.86M	86.29M	50.71M	25.56M	10.86M
General & Administrative	155.80M	163.96M	206.64M	192.77M	61.40M	36.19M	36.78M	9.92M
Selling & Marketing	295.23M	299.83M	191.88M	106.51M	78.34M	53.47M	32.50M	26.19M
SG&A	451.03M	463.78M	398.52M	299.28M	139.73M	89.66M	69.27M	36.11M
Other Expenses	83.40M	-112.56M	25.18M	3.64M	88.00K	4.70M	-1.06M	-1.00K
Operating Expenses	901.62M	837.59M	661.74M	449.15M	226.03M	140.37M	94.84M	46.97M
Cost & Expenses	1.13B	993.92M	784.65M	541.68M	296.75M	183.58M	126.45M	69.10M
Interest Income	35.37M	6.07M	3.93M	10.17M	13.74M	5.27M	2.23M	733.00K
Interest Expense	2.58M	2.58M	2.58M	4.77M	1.18M	1.25M	2.70M	3.02M
Depreciation & Amortization	42.88M	35.96M	22.27M	16.07M	13.61M	7.14M	5.21M	3.69M
EBITDA	-433.31M	-614.91M	-359.62M	-225.07M	-54.93M	-75.84M	-75.31M	-39.42M
EBITDA Ratio	-76.83%	-144.79%	-102.21%	-84.10%	-31.97%	-91.54%	-140.91%	-156.13%
Operating Income	-564.73M	-544.38M	-411.00M	-254.95M	-82.37M	-92.94M	-76.61M	-43.85M
Operating Income Ratio	-100.14%	-121.10%	-110.00%	-88.92%	-38.42%	-102.54%	-153.71%	-173.66%
Total Other Income/Expenses	85.96M	-109.07M	26.53M	9.05M	12.65M	8.72M	-6.60M	-2.29M
Income Before Tax	-478.76M	-653.45M	-384.47M	-245.90M	-69.72M	-84.23M	-83.21M	-46.13M
Income Before Tax Ratio	-84.90%	-145.36%	-102.89%	-85.76%	-32.52%	-92.92%	-166.96%	-182.71%
Income Tax Expense	685.00K	1.14M	300.00K	379.00K	-1.87M	38.00K	7.00K	6.00K
Net Income	-479.45M	-654.59M	-384.77M	-246.28M	-67.85M	-85.06M	-83.22M	-46.14M
Net Income Ratio	-85.02%	-145.61%	-102.98%	-85.89%	-31.65%	-93.85%	-166.97%	-182.74%
EPS	-4.28	-6.41	-3.80	-2.53	-0.75	-2.80	-1.18	-0.65
EPS Diluted	-4.28	-6.41	-3.80	-2.53	-0.75	-2.80	-1.18	-0.65
Weighted Avg Shares Out	111.99M	102.18M	101.31M	97.50M	90.60M	30.40M	70.72M	70.72M
Weighted Avg Shares Out (Dil)	111.99M	102.18M	101.31M	97.50M	90.60M	30.40M	70.72M	70.72M

Guardant Health Stock Flashing Surefire ‘Buy' Signal

December 4, 2024forbes.com

Biotechnology stock Guardant Health (GH) is trading at 15-month highs today, last seen up 7% at $38.28. Shares have added 107.7% over the last nine months, and now stand nearly 42% higher in 2024.

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

November 25, 2024prnewswire.com

Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera Found to Have Willfully Misled Oncologists in an Effort to Thwart Competition PALO...

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 13, 2024businesswire.com

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 233,603 shares of...